key: cord-0947761-0843pyf3
authors: Tan, Haozhou; Ma, Chunlong; Wang, Jun
title: Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
date: 2022-05-12
journal: Med Chem Res
DOI: 10.1007/s00044-022-02903-0
sha: e00a560f1af21d0452735bbccb6bec5223e867c2
doc_id: 947761
cord_uid: 0843pyf3

The COVID-19 pandemic spurred a broad interest in antiviral drug discovery. The SARS-CoV-2 main protease (M(pro)) and papain-like protease (PL(pro)) are attractive antiviral drug targets given their vital roles in viral replication and modulation of host immune response. Structurally disparate compounds were reported as M(pro) and PL(pro) inhibitors from either drug repurposing or rational design. Two polyphenols dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) were recently reported as SARS-CoV-2 M(pro) inhibitors. With our continuous interest in studying the mechanism of inhibition and resistance of M(pro) inhibitors, we report herein our independent validation/invalidation of these two natural products. Our FRET-based enzymatic assay showed that neither dieckol nor PGG inhibited SARS-CoV-2 M(pro) (IC(50) > 20 µM), which is in contrary to previous reports. Serendipitously, PGG was found to inhibit the SARS-CoV-2 PL(pro) with an IC(50) of 3.90 µM. The binding of PGG to PL(pro) was further confirmed in the thermal shift assay. However, PGG was cytotoxic in 293T-ACE2 cells (CC(50) = 7.7 µM), so its intracellular PL(pro) inhibitory activity could not be quantified by the cell-based Flip-GFP PL(pro) assay. In addition, we also invalidated ebselen, disulfiram, carmofur, PX12, and tideglusib as SARS-CoV-2 PL(pro) inhibitors using the Flip-GFP assay. Overall, our results call for stringent hit validation, and the serendipitous discovery of PGG as a putative PL(pro) inhibitor might worth further pursuing. [Figure: see text]

Introduction COVID-19 is caused by the SARS-CoV-2, an enveloped, single-stranded, and positive-sense RNA virus [1] . Seven coronaviruses are known to infect humans including four common human coronaviruses OC43, 229E, NL63, and HKU1, and three highly pathogenic coronaviruses SARS-CoV, SARS-CoV-2 and MERS-CoV [2] . The COVID-19 pandemic is a timely call for the urgent need of orally bioavailable antivirals. Drug repurposing plays a pivotal role in combating emerging diseases such as COVID19 [3] . For example, the first FDA-approved COVID drug, remdesivir, was originally developed for Ebola virus [4] , and was later found to have broad-spectrum antiviral activity against several viruses including SARS-CoV, MERS-CoV, and SARS-CoV-2 [5, 6] . Similarly, molnupiravir was a clinical candidate for the influenza virus before being repurposed for SARS-CoV-2 [7, 8] . The SARS-CoV-2 main protease (M pro ) and papain-like protease (PL pro ) are also high-profile viral proteins for targetbased drug repurposing. Numerous virtual screenings and high-throughput screenings have been conducted, revealing structurally disparate inhibitors that are at different stages of preclinical and clinical development [9] . For example, boceprevir [10, 11] , calpain inhibitors [10] , GC-376 [10, 12] , and masitinib [13] were among the first hits reported as M pro inhibitors. GRL0617 [14, 15] , YM155 [16] , 6-thioguanine [17] , SJB2-043 [18] , and others were identified as PL pro inhibitors. Natural products have always been a rich source of modern medicine [19] , and multiple natural products have been reported as M pro and PL pro inhibitors [20] . For example, two polyphenols dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) were recently reported as SARS-CoV-2 M pro inhibitors [21, 22] . With our continuous interest in validation/invalidation of literature reported SARS-CoV-2 M pro and PL pro inhibitors [23] [24] [25] [26] , we report herein our independent validation of these two compounds using the established FRET enzymatic assay and cell-based Flip-GFP assay. In addition, we further confirmed that the previously reported promiscuous cysteine modifiers ebselen, disulfiram, carmofur, PX12, and tideglusib [27] are not PL pro inhibitors, despite the claim from several publications that they act as PL pro inhibitors [28, 29] . Interestingly, we serendipitously discovered PGG as a PL pro inhibitor and showed that PGG binds to PL pro and inhibited the enzymatic activity of PL pro in the FRET assay. Taken together, our results call for stringent hit validation, and the serendipitous discovery of PGG as a putative PL pro inhibitor might worth further investigation.

Invalidation of dieckol and PGG as SARS-CoV-2 M pro inhibitors and validation of PGG as a PL pro inhibitor Dieckol was reported as a SARS-CoV-2 M pro inhibitor through a fluorescence polarization-based high-throughput screening [21] . In the assay design, the biotin-labeled M pro substrate was conjugated with a fluorescein isocyanate (FITC) fluorophore, resulting in a bifunctional probe FITC-AVLQ ↓ SGFRKK-Biotin (FITC-S-Biotin). Binding of this probe to avidin led to increased fluorescence polarization. Upon M pro digestion, the fluorophore-peptide conjugate FITC-AVLQ was released, resulting in reduced millipolarization unit (mP) signal. Screening of a natural product library of 5,000 compounds identified dieckol as a potent M pro inhibitor with IC 50 values of 4.5 µM (no DTT) and 2.9 µM (1 mM DTT). The mechanism of action was characterized using the FRET assay and surface plasmon resonance binding assay, both of which showed consistent results with the FP assay. Enzymatic kinetic studies demonstrated that dieckol is a competitive M pro inhibitor. It is noted that dieckol was also previously reported as a SARS-CoV M pro inhibitor [30] .

PGG was reported as an inhibitor for both SARS-CoV and SARS-CoV-2 M pro with IC 50 values of 6.89 and 3.66 µM, respectively [22] . In another study, PGG was found to bind to the SARS-CoV-2 spike protein receptor binding domain (RBD) with a K D of 6.69 µM in the biolayer interferometry assay, while the binding of PGG to the ACE2 receptor was weaker with a K D of 22.2 µM [31] . PGG was further shown to block the RBD-ACE2 interactions in the ELISA assay with an IC 50 of 46.9 µM. In the SARS-CoV-2 pseudovirus assay, PGG dose-dependently inhibited the viral entry and replication.

To validate whether dieckol and PGG are M pro inhibitors, we repeated the FRET enzymatic assay using our standard FRET assay condition (20 mM HEPES, pH 6.5, 120 mM NaCl, 0.4 mM EDTA, 4 mM DTT, and 20% glycerol). Both dieckol and PGG were inactive (IC 50 > 20 µM) ( Table 1) . To examine whether dieckol and PGG inhibited the intracellular protease activity of M pro , we characterized both compounds in the cell-based Flip-GFP M pro assay. Our previous results showed that there is generally a positive correlation between the Flip-GFP and antiviral assay results, while the correlation between the FRET enzymatic assay results and antiviral assay results is compound dependent [15] . In the Flip-GFP assay, the GFP is reconstituted upon cleavage of the engineered linker by M pro , and the normalized GFP/mCherry signal ratio is proportional to the M pro activity (mCherry serves as an internal control for the protein expression level or compound toxicity) [32, 33] . GC-376 was included as a positive control and it showed an EC 50 of 3.5 µM (Fig. 1A) . The results showed that both dieckol and PGG lacked the cellular M pro inhibitory activity at non-toxic drug concentrations (Fig. 1A) . Dieckol was not active (IC 50 > 60 µM), while PGG was cytotoxic (CC 50 = 9.8 µM) (Fig. 1A) , therefore the result was not conclusive. Taken together, dieckol and PGG were both invalidated as M pro inhibitors.

In parallel, we tested dieckol and PGG against SARS-CoV-2 PL pro in the FRET assay. While dieckol was not active (IC 50 > 20 µM), PGG was serendipitously found to inhibit SARS-CoV-2 PL pro with an IC 50 of 3.9 µM (Fig. 1B and Table 1 ). To profile the broad-spectrum activity, PGG was tested against SARS-CoV and MERS-CoV PL pro . PGG showed weak activity against SARS-CoV PL pro with an IC 50 of 12.3 µM, while it was inactive against the MERS-CoV (IC 50 > 60 µM) (Fig. 1B) . These results suggest that the inhibition of SARS-CoV-2 PL pro by PGG might be specific. We further characterized the binding of PGG to SARS-CoV-2 PL pro in the thermal shift assay and found that PGG increased the thermal stability of PL pro in a dose dependent manner (Fig. 1C) . To determine whether PGG inhibits the intracellular protease activity of SARS-CoV-2 PL pro , we performed the Flip-GFP PL pro assay. Unfortunately, PGG was cytotoxic to the 293 T cells used in the Flip-GFP PL pro assay (CC 50 = 7.7 µM), resulting in inconclusive results (Fig. 1D) .

To gain insights of the binding mode, we performed molecular docking of PGG with SARS-CoV-2 PL pro (PDB: 7JRN) [15] using the Schrödinger Glide extra-precision. The binding sites in PL pro were determined by the sitemap, which revealed the BL2 loop region as the highest-ranking binding site, therefore it was selected for PGG docking. The BL2 loop region is also the drug binding site of the known PL pro inhibitors GRL0617 [15] . Docking results showed that PGG fits snugly in the binding site with a Glide score of −10.024 kcal/mol ( Fig. 2A) . PGG formed multiple hydrogen bonds with PL pro residues including the side chains of Tyr273, Asp302, Arg166, Lys157 and the main chain of Leu162 (Fig. 2B) .

Disulfiram was previously reported as an inhibitor of both SARS-CoV and MERS-CoV PL pro s [28] . Enzymatic kinetic studies showed that disulfiram acts as an allosteric inhibitor of MERS-CoV PL pro and a competitive inhibitor of the SARS-CoV PL pro . In contrary, our previous study revealed that the inhibition of SARS-CoV-2 PL pro by disulfiram in the FRET-based enzymatic assay is reducing reagent dependent [25] . Disulfiram inhibited SARS-CoV-2 PL pro with an IC 50 of 6.9 µM in the absence of DTT but was not active in the presence of DTT (IC 50 > 60 µM) (Table 1) . Likewise, ebselen, carmofur, PX-12, and tideglusib all showed various degrees of inhibition against the SARS-CoV-2 PL pro in the absence of DTT, while the inhibition was abolished in the presence of DTT (Table 1 ) [25] . In contrary, Weglarz-Tomczak et al. reported that ebselen inhibited SARS-CoV and SARS-CoV-2 PL pro s with IC 50 values of 8.45 and 2.26 µM, respectively, in the presence of 2 mM DTT [29] . Disulfiram and ebselen were also proposed to inhibit SARS-CoV-2 PL pro through ejecting zinc from the zinc-binding domain [34] . Given the debate whether reducing reagent should be added to the cysteine protease assay buffer, coupled with the controversial FRET assay results of ebselen in the presence of DTT, we were interested in further characterizing the inhibition of SARS-CoV-2 PL pro by these compounds in a native cellular environment. For this, we employed our recently established cellular Flip-GFP PL pro assay [15] to test the intracellular activity of these compounds. It was found that none of the compounds tested reduced the GFP/mCherry ratio at non-cytotoxic concentrations (Fig. 3A-F) , suggesting that they lack the intracellular target engagement and PL pro inhibition. Collectively, our data suggest that disulfiram, ebselen, carmofur, PX-12, and tideglusib should not be classified as PL pro inhibitors. 

In conclusion, our data suggested that dieckol and PGG are not M pro inhibitors as shown from the FRET and Flip-GFP M pro assays. Furthermore, the previous reported promiscuous cysteine modifiers ebselen, disulfiram, carmofur, PX-12, and tideglusib were also invalidated as PL pro inhibitors by the Flip-GFP PL pro assay. Taken together with our previous efforts in invalidating these compounds as M pro inhibitors, it can be concluded that M pro and PL pro enzymatic assay IC 50 results obtained in the absence of reducing reagents have no correlation with their cellular activity. Among the list of compounds examined, ebselen was previously shown to inhibit SARS-CoV-2 viral replication in cell culture [27, 35] . Coupled with the results presented here, it appears that the antiviral mechanism of action of ebselen is independent of either M pro or PL pro inhibition.

Since the FRET assay conditions used in different labs vary, it might be challenging to directly compare the results. Nonetheless, the cell-based Flip-GFP assay is a valuable tool in evaluating the intracellular protease activity and is a close mimetic of virus-infected cells.

In summary, the results presented herein call for stringent hit validation before investing resources for lead optimization and translational antiviral development. The discovery of PGG as a PL pro inhibitor provides another starting point for further optimization.

All compounds were purchased from commercial source without further purification. PGG was ordered from Toronto Research Chemical with the Cat # P270450.

SARS-CoV-2 main protease (M pro ) gene from strain Beta-CoV/Wuhan/WIV04/2019 (GenBank: MN996528.1) was purchased from GenScript (Piscataway, NJ) with E. coli codon optimization and was inserted into pET29a(+) plasmid. The M pro genes were then subcloned into the pE-SUMO plasmid as previously described [10, 36] . The expression and purification procedures were previously described [10] . SARS-CoV-2 papain-like protease (PL pro ) gene (ORF 1ab 1564-1876) from strain BetaCoV/Wuhan/WIV04/2019 with E. coli codon optimization was ordered from GenScript in the pET28b(+) vector. The detailed expression and purification procedures were previously described [15] .

For the IC 50 measurement with the FRET-based assay, the reaction was carried out in 96-well format with 100 μL of 200 nM PL pro protein in a PL pro reaction buffer (50 mM Fig. 3 Invalidation of disulfiram, ebselen, carmofur, PX-12, and tideglusib as SARS-CoV-2 PL pro inhibitors using the Flip-GFP PL pro assay. GRL0617 (A) was included as a positive control. % (GFP/ mCherry) ratio correlates with intracellular PL pro activity, and % mCherry signal correlates with compound toxicity or transfection efficiency. The results are mean ± standard deviation of two repeats HEPES (pH 7.5), 5 mM DTT, and 0.01% Triton X-100); 1 μL of testing compounds at various concentrations was added to each well and was incubated at 30°C for 30 min. The reaction was initiated by adding 1 μL of 1 mM FRET substrate and was monitored in a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30°C for 1 h. The initial velocity of the enzymatic reaction was calculated from the initial 10 min enzymatic reaction. The IC 50 was calculated by plotting the initial velocity against various concentrations of testing compounds using a four-parameter variable slope dose-response curve in Prism 8 software. IC 50 values for the testing compounds against SARS-CoV-2 M pro was determined as previously described [10] .

Plasmid pcDNA3-TEV-FlipGFP-T2A-mCherry was ordered from Addgene (catalog No.124429). pcDNA3 FlipGFP-M pro plasmid and pcDNA3 FlipGFP-PL pro plasmid were constructed by introducing SARS-CoV-2 M pro cleavage site AVLQSGFR and SARS-CoV-2 PL pro cleavage site LRGGAPTK, respectively, via overlapping PCRs. pLVX SARS-CoV-2 M pro and pcDNA3.1 SARS-CoV-2 PL pro plasmids was ordered from Genescript (Piscataway NJ) with codon optimization.

The Flip-GFP M pro and PL pro assays were performed as previous reported [15, 23, 24, 37] . Briefly, the assay started with seeding 293T-ACE2 in 96-well, black, clear bottomed plate (Greiner, catalog No. 655090) and incubating overnight to allow cells to reach 70-80% confluency. 50 ng of pLVX SARS-CoV-2 M pro (or pcDNA3.1 SARS-CoV-2 PL pro ) and 50 ng of pcDNA3 FlipGFP-M pro (or pcDNA3 FlipGFP-PL pro ) reporter plasmid was mixed with transfection reagent TransIT-293 (Mirus, catalog No. MIR 2700). The mixture was then transfected to each well according to manufacturer's instructions. After 2.5-3 hours of incubation in 37°C, 1 μL of testing compound was added into each well directly and mixed by gentle plate shaking. 48 h post transfection, fluorescence was quantified using SpectraMax iD3 plate reader (Molecular Devices) and images were taken using BZ-X800E fluorescence microscope (Keyence) in GFP and mCherry channels at 4X objective lens.

The thermal shift binding assay (TSA) was carried out using a Thermo Fisher QuantStudio 5 Real-Time PCR system as described previously [10] .

Docking of PGG in SARS-CoV-2 PL pro was performed using the Schrödinger Glide extra precision program. The X-ray crystal structure of SARS-CoV-2 PL pro in complex with GRL0617 (PDB: 7JRN) was chosen for the docking. The gride box was centered on GRL0617. The docking poses were visualized using Pymol.

Characteristics of SARS-CoV-2 and COVID-19

Coronavirus biology and replication: implications for SARS-CoV-2

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Drug development and medicinal chemistry efforts toward SARScoronavirus and Covid-19 therapeutics

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay

Highthroughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of

Drug repurposing for the SARS-CoV-2 papain-like protease

Natural products with potential to treat RNA virus pathogens including SARS-CoV-2

A review on potential of natural products in the management of COVID-19

Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors

The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease

Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

PX-12, Tideglusib, and Shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors

chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Structure of M (pro) from SARS-CoV-2 and discovery of its inhibitors

Disulfiram can inhibit MERS and SARS coronavirus papainlike proteases via different modes

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2

SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava

1,2,3,4,6-pentagalloyl glucose, a RBD-ACE2 binding inhibitor to prevent SARS-CoV-2 infection

Development of a fluorescence-based, high-throughput SARS-CoV-2 3CL(pro) reporter assay

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles

Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L

Discovery of di-and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity

Acknowledgements This research was supported by the National Institutes of Health (NIH) (grants AI147325, AI157046, and AI158775) to J.W.

Conflict of interest The authors declare no competing interests.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.